28 results
424B3
ATXI
Avenue Therapeutics Inc
2 Feb 24
Prospectus supplement
12:00am
indications (other than androgenetic alopecia and Alzheimer’s disease) in the United States, Canada, the European Union, the United Kingdom and Israel
8-K
EX-10.2
ATXI
Avenue Therapeutics Inc
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’ employees is a member of a union that relates
8-K
EX-1.1
k63v2r 61p4ii
12 Oct 22
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
9:00am
424B4
t87jy7elp u9dv0al
11 Oct 22
Prospectus supplement with pricing info
8:27am